State of Possible: Strand Therapeutics' Co-Founder & CEO Jake Becraft talks mRNA and getting into the clinic with the company's first program

blonca9
Mar 26
1 min read

He describes the intratumoral IL-12 program that is in the clinic today, and the preclinical progress Strand is making on its other programs. Plus, his thoughts on the current public perception of mRNA.

Recent Posts

See All

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

State of Possible: Strand Therapeutics' Co-Founder & CEO Jake Becraft talks mRNA and getting into the clinic with the company's first program

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight